Christophe Bourdon, LEO Pharma CEO, on Dermatology Innovation, Rare Disease & Scalable Growth

Synopsis: At a moment when biotech is rethinking growth, innovation, and patient impact, Alok Tayi sits down with Christophe Bourdon, Chief Executive Officer of LEO Pharma, to explore what it truly means to build a purpose-driven, commercial-stage biotech. Drawing on three decades across Sanofi, Alexion, Amgen, and now LEO Pharma, Christophe shares a clear conviction: innovation only matters when it meaningfully changes patients’ lives. At LEO Pharma, that belief is shaping a focused strategy in medical dermatology, where over one-third of the global population is affected and thousands of skin diseases still lack approved treatments. The conversation spans LEO Pharma’s evolution into a nearly $2B growth company, the rise of first-in-class therapies in atopic dermatitis and chronic hand eczema, and why formulation science, rare disease execution, and “white-glove” patient support are essential to changing standards of care. Christophe also offers sharp perspectives on AI-enabled scouting, the accelerating innovation coming out of China, and why biotech must resist “me-too” products in favor of true clinical breakthroughs. From JPMorgan Healthcare Conference insights to deeply human stories of rare disease care at 4 a.m., this episode is a masterclass in disciplined growth, differentiated innovation, and patient-first leadership. Biography: Christophe joined LEO Pharma as CEO in April 2022 and has since led the company through a strategic transformation, sharpening its focus on innovation and external partnerships. Under his leadership, LEO Pharma has accelerated growth in key markets, advanced its pipeline, and strengthened its culture, reinforcing its position as a global leader in medical dermatology. Before joining LEO Pharma, he served as CEO of Orphazyme A/S. Earlier in his career, he held senior leadership roles at Amgen, including Senior Vice President and General Manager for the U.S. Oncology Business, and at Alexion as Senior Vice President, EMEAC, overseeing the commercial development of ultra-orphan therapies across 40 countries. Christophe holds an MBA from the International Institute for Management Development (IMD) in Lausanne, Switzerland, and a B.A. from the Institut Supérieur de Gestion (ISG) in Paris, France.